clinical trial · NCT06554184
HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents
Fujian Shengdi Pharmaceutical Co., Ltd.·phase3·completed·n = 706
Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer AgentsHR20013 + dexamethasone + palonosetron placeboPalonosetron + dexamethasone + HR20013 placebo
brief summary
This study is aimed to evaluate the efficacy and safety of HR20013 versus palonosetron for nausea and vomiting associated with moderate emetic risk anticancer agents
started
Sep 3, 2024
primary completion
Jul 28, 2025
completion
Oct 3, 2025
last updated
Nov 17, 2025
official title
A Randomized Phase III Study Evaluating the Efficacy and Safety of HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol